US News & World Report - Biotech Stocks

RE: Jonathan P. GertlerBack Bay Life Science Advisors Quoted in US News & World Report Article on “Would Hilary Clinton Be Bad for Biotech Stocks”Back Bay’s Managing Partner and CEO, Jonathan Gertler, was quoted in US News & World article on “Would Hilary Clinton Be Bad for Biotech Stocks”

Here’s an excerpt from the article.

Jonathan Gertler, CEO and managing partner of Back Bay Life Science Advisors, agrees with Kimmel that a Clinton administration would not needlessly regulate the pharma and biotech industries or damage either’s overall investability. But it’s not the sway of K Street that has him convinced. Dramatic overregulation, simply put, would be downright irrational.“Those novel drugs that really have an impact on society have expenses associated with them, and I think any oversight agency will recognize the need to support return on investment for that type of contribution,” he says.Gertler feels that Clinton’s support for science and education shows her policies will be a boon to the health care sector. “Hillary has long been an advocate of data-driven approaches to how science fits in our society," he says. "That’s going to be beneficial for our country and our industry.”The public and private sectors have increasingly teamed up to work on unmet needs in health care, a trend Gertler sees continuing under Clinton.“Investing in innovation and our scientific sector, which translates – whether it’s five or 20 years later – into benefits on a clinical and therefore commercial level, I don’t think that’s at all what’s under attack by her statements,” he says.